Parabilis Medicines completed a record IPO on Nasdaq, raising $670 million as detailed in the provided content, adding to a rapid run of large biotech listings. The post notes Parabilis’ listing overtook Kailera Therapeutics’ prior record benchmark from April, with other biotechs including Avalyn Pharma, Seaport Therapeutics, and Odyssey Therapeutics also entering the public markets. The coverage ties the uptick to years of under-deployed pandemic-era capital and improved pathways for follow-on financing, alongside an acquisition market that can validate platforms and clinical signals. It also flags that macro uncertainty has not prevented companies with late-stage or differentiated pipelines from accessing public funding. For biotech leadership teams, the message is clear: liquidity is returning for selected stories, and investor appetite appears to be shifting toward teams with near-term clinical or asset catalysts.